New hope for men battling hot flashes from prostate cancer treatment
NCT ID NCT06957691
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times
Summary
This study tests a drug called fezolinetant to see if it can reduce hot flashes in men with prostate cancer who are on hormone therapy (androgen deprivation therapy). About 60 men will take either the drug or a placebo daily for 4 weeks. Researchers will track hot flash frequency, severity, and impact on quality of life, while also checking for liver safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDROGEN ABLATIVE THERAPY OF ADVANCED HORMONE-DEPENDENT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a new tracer light up hidden prostate cancer?
- Shockwaves may speed up erectile recovery after prostate cancer surgery
- Could deep breaths before surgery ward off Post-Op confusion?
- A sharper eye on prostate cancer return: PSMA PET vs. MRI
- A second look: MRI screening may spot hidden prostate cancers